Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;23(18):2023-2034.
doi: 10.1080/14656566.2022.2128670. Epub 2022 Sep 27.

Current and future pharmacotherapy options for drug-resistant epilepsy

Samia Elkommos  1   2 , Marco Mula  2   3
Affiliations
Review

Current and future pharmacotherapy options for drug-resistant epilepsy

Samia Elkommos et al. Expert Opin Pharmacother. 2022 Dec.

Abstract

Introduction: Epilepsy is a common neurological condition, affecting over 70 million individuals worldwide.

Areas covered: The present paper reviews current and future (under preclinical and clinical development) pharmacotherapy options for the treatment of drug-resistant focal and generalized epilepsies.

Expert opinion: Current pharmacotherapy options for drug-resistant epilepsy include perampanel, brivaracetam and the newly approved cenobamate for focal epilepsies; cannabidiol (Epidiolex) for Lennox-Gastaut Syndrome (LGS), Dravet and Tuberous Sclerosis Complex (TSC); fenfluramine for Dravet syndrome and ganaxolone for seizures in Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. Many compounds are under clinical development and may hold promise for future pharmacotherapies. For adult focal epilepsies, padsevonil and carisbamate are at a more advanced Phase III stage of clinical development followed by compounds at Phase II like selurampanel, XEN1101 and JNJ-40411813. For specific epilepsy syndromes, XEN 496 is under Phase III development for potassium voltage-gated channel subfamily Q member 2 developmental and epileptic encephalopathy (KCNQ2-DEE), carisbamate is under Phase III development for LGS and Ganaxolone under Phase III development for TSC. Finally, in preclinical models several molecular targets including inhibition of glycolysis, neuroinflammation and sodium channel inhibition have been identified in animal models although further data in animal and later human studies are needed.

Keywords: Epilepsy; antiepileptic drugs; carisbamate; cenobamate; fenfluramine; ganaxolone; padsevonil.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Supplementary concepts

-